Mobius Therapeutics™ is a commercial stage venture focused upon perioperative sterile injectables used in ophthalmic surgery. Its first product, Mitosol®, is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Mobius maintains an active sterile injectable product pipeline in varying stages of development. Please see full prescribing information at www.Mitosol.com and www.EyeAmphadase.com.
Looking for a particular Mobius Therapeutics employee's phone or email?
The Mobius Therapeutics annual revenue was $11 million in 2026.
Ed Timm is the Founder and Chief Executive Officer of Mobius Therapeutics.
8 people are employed at Mobius Therapeutics.
Mobius Therapeutics is based in St. Louis, Missouri.
The NAICS codes for Mobius Therapeutics are [32, 325, 3254, 32541].
The SIC codes for Mobius Therapeutics are [283, 28].